Breaking News, Trials & Filings

Trials & Filings in Brief: Oct. 8, 2013

Acorda, Alkermes, Alnylam, Cornerstone, Eleison, and Keryx

Preclinical
Alnylam advances ALAS-1 attacker . . . read more

Phase I
Acorda begins second HF trial of GGF2 . . . read more

Phase III
Alkermes completes patient enrollment . . . read more

Filings
Cornerstone MDS drug gets orphan status . . . read more

Eleison gets orphan status from EC for osteosarcoma treatment . . . read more

FDA Accepts Keryx NDA for Zerenex . . . read more

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters